UCB, a global biopharmaceutical company, announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint...
Virax Biolabs Group Limited a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief Executive Officer James Foster providing...
UCB, a global biopharmaceutical company, announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit...
Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major...